e.g. mhealth
Search Results (1 to 10 of 10 Results)
Download search results: CSV END BibTex RIS
Skip search results from other journals and go to results- 3 JMIR Research Protocols
- 3 Journal of Medical Internet Research
- 2 JMIR Cancer
- 1 JMIR Formative Research
- 1 JMIR Public Health and Surveillance
- 0 Medicine 2.0
- 0 Interactive Journal of Medical Research
- 0 iProceedings
- 0 JMIR Human Factors
- 0 JMIR Medical Informatics
- 0 JMIR mHealth and uHealth
- 0 JMIR Serious Games
- 0 JMIR Mental Health
- 0 JMIR Rehabilitation and Assistive Technologies
- 0 JMIR Preprints
- 0 JMIR Bioinformatics and Biotechnology
- 0 JMIR Medical Education
- 0 JMIR Challenges
- 0 JMIR Diabetes
- 0 JMIR Biomedical Engineering
- 0 JMIR Data
- 0 JMIR Cardio
- 0 Journal of Participatory Medicine
- 0 JMIR Dermatology
- 0 JMIR Pediatrics and Parenting
- 0 JMIR Aging
- 0 JMIR Perioperative Medicine
- 0 JMIR Nursing
- 0 JMIRx Med
- 0 JMIRx Bio
- 0 JMIR Infodemiology
- 0 Transfer Hub (manuscript eXchange)
- 0 JMIR AI
- 0 JMIR Neurotechnology
- 0 Asian/Pacific Island Nursing Journal
- 0 Online Journal of Public Health Informatics
- 0 JMIR XR and Spatial Computing (JMXR)
Benign prostatic hyperplasia (BPH) is the progressive enlargement of the prostate gland as a result of the nonmalignant proliferation of epithelial and stromal cells [1,2]. BPH is an age-related disease. It has been reported that over half of the Chinese male population aged 70 years or older are experiencing BPH [3]. The pathogenesis of BPH remains incompletely understood despite its high prevalence, as multiple factors are involved in the process [4].
JMIR Public Health Surveill 2024;10:e53673
Download Citation: END BibTex RIS
Prostate-specific antigen (PSA) is a protein produced by the prostate gland, and its levels in the blood are commonly used as a marker in the assessment of prostate health. PSA levels are measured using an immunoassay, and elevated levels can be indicative of prostate conditions including benign prostatic hyperplasia or prostate cancer.
JMIR Cancer 2024;10:e60323
Download Citation: END BibTex RIS
Patients with prostate cancer (PCa) undergoing radiation therapy (RT) are asked to self-manage bladder volumes throughout their daily radiation treatments. A consistent and comfortably full bladder is important to (1) minimize treatment-related toxicity by decreasing radiation dose to adjacent normal organs, and (2) to potentially maximize treatment precision by decreasing prostate motion and improving target stabilization.
JMIR Cancer 2024;10:e51061
Download Citation: END BibTex RIS
The rate of prostate cancer survivorship is increasing, but this comes with its own challenges such as escalating health care costs and large numbers of survivors requiring ongoing care [4]. In this context, shared decision-making becomes pivotal, particularly concerning prostate-specific antigen screening and prostate cancer treatment selection [4].
J Med Internet Res 2024;26:e55939
Download Citation: END BibTex RIS
To improve disease knowledge and facilitate SDM, our research group has developed several interactive, Internet-based decision aids for patients with prostate cancer [10-12] and those with breast cancer. The Prostate Interactive Education System (PIES) and the second-generation Healing Choices programs for prostate and breast cancer are comprehensive educational and decision tools that include several hours of text information and video-based testimonials.
J Med Internet Res 2023;25:e46552
Download Citation: END BibTex RIS
Prostate cancer is the leading cancer diagnosed in men in France, with 50,400 new cases and 8100 deaths in 2018. Improved diagnostic strategies and therapeutic management have led to a 3.7% reduction in mortality between 2010 and 2018, and the survival rate is 93% at 5 years and 80% at 10 years [1], resulting in improved overall survival.
JMIR Res Protoc 2023;12:e38362
Download Citation: END BibTex RIS
The same test was then used to analyze patients on hormone therapy and those with no hormone therapy for 2 types of cancer—breast cancer and prostate cancer. R (version 4.1.2; R Foundation for Statistical Computing) was used to conduct all the statistical analyses in this study, and a P
This observational prospective study was approved by the institutional review board of Rafael Institute and the ethical committee of Hartmann Oncology Radiotherapy Group. Informed consent was obtained from each participant.
JMIR Form Res 2022;6(11):e37371
Download Citation: END BibTex RIS
According to the GLOBOCAN worldwide estimates of cancer incidence and mortality produced by the International Agency for Research on Cancer, there were 1,111,700 new cases of prostate cancer and 307,500 prostate cancer deaths in 2012, making prostate cancer the second most commonly diagnosed cancer in men and the fifth leading cause of cancer deaths among men [1].
Screening for prostate cancer remains a controversial issue, particularly after data from two major trials were released.
J Med Internet Res 2018;20(6):e228
Download Citation: END BibTex RIS
Focal therapy selection with mp MRI-targeted biopsies may be an option in experienced hands, but to date, there is a substantial proportion of false positives in lesions 3/5 or 4/5 scored with the prostate imaging reporting data system (PI-RADS) [9]. Moreover, the assessment of mp MRI-negative areas or the prostate as a whole using a transperineal prostate mapping biopsy using a template-guided approach is recommended [2,10,11].
JMIR Res Protoc 2018;7(5):e132
Download Citation: END BibTex RIS
Hemiablative Focal Low Dose Rate Brachytherapy: A Phase II Trial Protocol
Prostate cancer is the most commonly diagnosed non-cutaneous neoplasm in males in the United States and the second leading cause of cancer mortality. Estimated new cases and deaths from prostate cancer in 2014 were 233,000 and 29,480, respectively. [1].
Widespread screening with the prostate-specific antigen (PSA) test, which can identify patients with asymptomatic tumors that have little or no lethal potential, has decreased the age of diagnosis [2].
JMIR Res Protoc 2016;5(2):e98
Download Citation: END BibTex RIS